Findings showed no significant reduction in cognitive or functional decline with simufilam when compared with placebo. Topline results were announced from a phase 3 trial evaluating simufilam, an oral ...

Please provide your email address to receive an email when new articles are posted on . Topline results from the phase 3 ReThink-ALZ study of simufilam in mild to moderate Alzheimer’s disease showed ...

No significant reduction in cognitive or functional decline was observed with simufilam compared with placebo. A phase 3 trial evaluating simufilam for the treatment of Alzheimer disease (AD) did not ...

Cassava Sciences Inc. (NASDAQ:SAVA) on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. REFOCUS-ALZ randomized approximately ...

The third interim safety review for simufilam showed no significant safety concerns, particularly regarding amyloid-related imaging abnormalities (ARIAs). Despite interim safety results, simufilam's ...

An independent DSMB reviewed interim safety data for simufilam and recommended the trials proceed without modifications. Two ongoing trials with over 1,900 Alzheimer’s patients; top-line results from ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials signals ...

Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease. Drug Effects Favored Mild Alzheimer’s Disease. In Mild Alzheimer’s, ...

Cassava Sciences SAVA recently suffered yet another setback, which raises concern regarding its prospects. Last week, the company announced that the phase III study REFOCUS-ALZ on lead pipeline ...